The Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function (CHMP/EWP/225/02) provides recommendations on when to conduct pharmacokinetic studies in patients with reduced renal function, design and evaluation of such studies and how to develop dosage recommendations in patients with renal impairment. This concept paper discusses the need to revise some sections of the guideline.
Go to Source

This entry was posted on Friday, June 8th, 2012 at 9:45 am and is filed under European Medicines Agency. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.